PRM60 The estimate of vaccination coverage rate using transmisson dynamic model: A example of pneumococcus vaccines  by Chang, C.J. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A191
PRM59
HeMatoPoietic steM cell tRansPlantation outcoMes: logistic 
RegRession Model develoPMent
Hatfield M.D.1, Kramer M.A.2, Johnson M.L.1
1University of Houston, Houston, TX, USA, 2The University of Texas MD Anderson Cancer Center, 
Houston, TX, USA
Objectives: The objective was to determine the most effective logistic regres-
sion models in terms of explaining the greatest amount of variance regarding four 
outcomes: graft versus host disease (GVHD), liver toxicity, neurotoxicity, and mor-
tality, among a cohort of patients undergoing hematopoietic stem cell transplanta-
tion. MethOds: Busulfan is used in combination with fludarabine or clofarabine 
as part of an effective chemotherapy based myeloablative preparative regimen for 
patients undergoing stem cell transplantation. Pharmacokinetic data regarding 
patient busulfan clearance was used in the analysis, since dosing is very sensi-
tive. Other clinically relevant covariates included: age, gender, race, primary can-
cer diagnosis, type of transplant (autologous or allogeneic), and prior transplant 
history. Descriptive statistics and logistic regression analyses were performed to 
assess the effect of these variables on each of four outcomes: GVHD, liver toxic-
ity, neurotoxicity, and mortality. Hosmer and Lemeshow goodness-of-fit tests and 
c-statistics were used to optimize the models. Only aggregate level information 
was reported. Statistical significance was set at 0.05. Results: Data on a cohort of 
752 patients undergoing hematopoietic stem cell transplantation were collected. 
Most patients were: 46.7±15.8 years old, male (59.8%), Caucasian (68.6%), with acute 
myeloid leukemia (28.9%), underwent an allogeneic transplant (67.0%), and had not 
received a prior transplant (93.5%). Controlling for the covariates listed, the mod-
els resulted in Hosmer and Lemeshow goodness-of-fit test statistics (chi-square, 
number of degrees of freedom, p-value) for each dependent variable as follows: GVHD 
(2.57, 5, 0.77); liver toxicity (5.17, 8, 0.74); neurotoxicity (8.45, 8, 0.39); and mortality 
(5.95, 8, 0.65). The c-statistics for each model were: GVHD (0.87); liver toxicity (0.74); 
neurotoxicity (0.75); and mortality (0.72). cOnclusiOns: The logistic regression 
models used were effective in determining the outcomes of GVHD, liver toxicity, 
neurotoxicity, and mortality, among a cohort of patients undergoing hematopoietic 
stem cell transplantation.
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Objectives: Vaccination coverage rate is usually obtained from the decision of 
an immunization policy. Actual impacts to the outcomes by different vaccinated 
recipients selection and their coverage rates were seldom discussed. This study 
aims to use a transmission dynamic model (TDM) based on a system of differen-
tial equations in susceptible-infectious-recovered model to optimally explore the 
estimates of coverage rates. MethOds: 23-valent pneumococcal polysaccharide 
vaccines (PPV23) and 13-valent pneumococcal conjugate vaccines (PCV13) have been 
shown their cost-effectiveness in elderly and children, respectively. Scenarios of 
PPV23 to the elderly aged 65+ years and PCV13 to children aged below 4 years were 
assumed and TDM was used. All epidemiological parameters were obtained from the 
Taiwan’s National Health Insurance Database and the vaccine efficacy was obtained 
from the literatures. Various vaccination coverage rates were considered. The equa-
tions were solved using the fourth-order Runge–Kutta method implemented in R 
Statistical Software. Results: The estimates of PPV23 for the elderly and PCV13 
for the children were both 70% to achieve optimal goal. Increasing the rate over 
70% will not significantly decrease the total number of pneumonia infection and 
death but increase the costs. cOnclusiOns: This study proposed an approach 
to estimate the optimal vaccination coverage rate based on the TDM simulations. 
This will provide value-based information of vaccination policy in the decision of 
vaccine quantity and recipients.
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Objectives: The objective of this paper is the analysis of practice or 
physicians’attributes in addition to patient or products ‘attributes to explain pat-
terns of drug utilization in predictive disease models including reversed conjoint 
data. In previous European physicians’cost sensitivity studies, physicians’ charac-
teristics such as demographics, solo/group practices, types of remuneration, location 
(depressed/wealthy areas) were not conclusive (ENDEP/biomed, 2003). This analysis 
explores additional physicians’attributes more related to professional activities 
(Rischatsch Zweifel,2012) such as referrals or restrictions to specialists, quality obli-
gations and incident reporting. MethOds: Different types of physicians’ choice 
sets are designed with sets of attributes classified in subgroups Z1,Z2,Z3 ( Z1 for 
products, Z2 for patients, Z3 for physicians’ attributes) . A sample of 688 patients 
diagnosed with diabetes type II without complications (ICD 250.00) is extracted 
from the National Medical Care Survey (Huttin/Wong, 2010). Practices are grouped 
by stages of IT computerization for billing and EMRs. Pharmacological treatment 
(including oral, injectables and supplies) is defined with a drug list from Facts and 
Comparisons over three successive years (e.g. 2004/2005/2006) for a 2005 database. 
Physicians’treatment choices are analyzed with a disease model integrating Z3 
physicians’attributes on subsets of physicians. The cumulative logistic model is 
run with SAS. Results: Results of the predictive disease model on diabetes type 
II show on the 2005 analytical dataset that drug utilization is much lower when 
physicians in clinical practice use a referral process (0.46). The stage of computeri-
zation of practices especially with ebilling remains highly significant (lower drug 
utilization when ebilling is used (0.69)). Additional runs are tested with predictive 
models on other chronic conditions (Asthma and Hypertension). cOnclusiOns: 
Objectives: CDC guidelines recommend hepatitis C virus (HCV) screening for 
the 1945-1965 birth cohorts. Since HCV prevalence is decreasing with birth-year, 
age-specific screening is less cost-effective in later cohorts. To inform the optimal 
time to discontinue screening, collecting additional information may be valu-
able, though when this information should be collected is unclear. MethOds: 
We apply a Markov decision process framework to evaluate how long to continue 
HCV screening in US men. We identify the optimal information collection policy 
for two parameters assumed constant across cohorts - reductions in quality-of-
life from awareness of HCV-positive status and the fibrosis-stage distribution at 
screen-detected diagnosis at age 50 - alone and in combination with information 
collection about HCV prevalence which is decreasing across cohorts. We estimate 
lifetime costs and benefits using a previously-developed HCV screening model and 
HCV prevalence dynamics derived from NHANES. The assumed willingness-to-
pay threshold is $75,000 per QALY. Results: The presence of a parameter which 
varies across cohorts influences the per-person value-of-information about both 
time-varying and static parameters. In these cases, we show analytically that it 
may be optimal to delay information collection. Given our prior beliefs, the optimal 
strategy is to collect sample information about the reduction in quality-of-life 
from awareness of HCV-positive status immediately and then, depending on the 
result of that study, collect information on HCV prevalence 3 to 20 years in the 
future. This strategy increases the expected incremental net monetary benefit by 
$2.3 million compared to a strategy of collecting information about both immedi-
ately. cOnclusiOns: We demonstrate that when parameters vary across cohorts, 
the optimal information collection policy, for both time-varying and static param-
eters, may be to delay information collection until it is more likely to influence 
the decision. Our dynamic programming framework enables the consideration of 
delayed information collection in numerous contexts.
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Objectives: There are few economic evaluations of strategies for screening, 
diagnosing, and treating autism spectrum disorder (ASD). The objective of this 
study was to create a discrete event simulation (DES) model of the pathway of 
care for children with suspected ASD up to age 6. This model will be used to 
perform economic evaluations of screening protocols, diagnostic tests and treat-
ments for ASD. MethOds: A DES model was conceived to simulate a Canadian 
population of children with suspected ASD. Attributes important for simulation 
of entities were identified from the literature and expert opinion. Important 
categories of attributes included ASD risk factors, ASD co-morbidities, meas-
ures of development, and measures of severity of ASD. The pathway of care 
was created with review of current practice guidelines as well as consultation 
with developmental pediatricians. Queuing for screening, diagnosis, and treat-
ment comes from entities accessing limited resources over a period of time. 
We will use calibration techniques to set resource and time limits to match 
the wait times reported in the literature. Results: A DES model was built for 
children with suspected ASD up to age 6. The DES model addresses population 
heterogeneity by including risk factors such as gender, autistic siblings, and older 
parents, genetic co-morbidities, and physical and psychological co-morbidities. 
The DES model simulates outcomes in terms of ASD severity, IQ, and language 
skills. The DES model addresses the issues of wait times that are relevant in 
ASD screening, diagnosis, and treatment by having entities queue for limited 
resources. cOnclusiOns: The DES modelling approach is well-suited to model-
ling the pathway of care for ASD patients. Patients with ASD have a wide variety 
of disabilities and co-morbidities that can be captured in DES modelling. DES 
modelling is also able to address issues of wait times that are prevalent in ASD 
screening, diagnosis, and treatment.
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Objectives: Congestive heart failure (CHF) is a major health burden with an 
increasing prevalence and incidence. Risk factors associated with recurrent CHF 
following surgical AVR has been previously described in a multivariate model by 
Ruel et al. The objective of this study was to re-create the previously described 
model without relying on the initial patient-level data. MethOds: The semipara-
metric Cox proportional hazards models described by Ruel et al. was based upon 
1563 patients who underwent AVR at the University of Ottawa Heart Institute 
between 1976 and 2001. Adjusted hazard ratios and mean covariate values were 
reported. Several distributions, including exponential, Weibull, and competing-
risks, were tested to determine, which would better reproduce the recurrent CHF 
function. Results: All candidate models successfully reproduced the published 
results by Ruel et al. One model was converted into a customizable excel model. 
Clinically relevant variables included in the re-created model included valve size, 
mean transprosthesis gradients, patient age, atrial fibrillation, preoperative NYHA 
class, body surface area, coronary artery disease, and smoking. After adjustment 
of patient and valve characteristics, the model predicted freedom from recur-
rent HF in the Ruel Cohort at 1, 5, 10, and 15 years as 98.4%, 90.8%, 73.2%, and 
43.5% compared with published values of 98.6%, 88.6%, 73.9%, and 45.2%, respec-
tively. cOnclusiOns: The re-created model accurately predicted CHF recurrence. 
Statistical models validated using large patient cohorts can be useful in population 
management.
